Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | SQLE | Q14534 | 7/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191493 | 0.92 | TSHR (0.52) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL160736 | 0.86 | KMT2A (0.64) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL83307 | 0.86 | KMT2A (0.64) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL29462483 | 0.86 | KMT2A (0.64) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL28588501 | 0.86 | KMT2A (0.64) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL9474487 | 0.84 | SQLE (0.70) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL9474498 | 0.84 | SQLE (0.70) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL9446281 | 0.83 | KMT2A (0.81) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL19571039 | 0.83 | KMT2A (0.81) | KMT2ASQLEALOX15MAPTMEN1 | |
| SCHEMBL7876849 | 0.83 | TSHR (0.46) | KMT2ASQLEALOX15MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11193078-B2 | Olefins and methods for making the same | Amyris, Inc. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190249101-A1 | OLEFINS AND METHODS FOR MAKING THE SAME | EUAGORE, LLC | 2019-08-15 | — | — | US | disclosed |
| EP-2697186-B1 | BASE OILS AND THEIR METHODS OF PRODUCTION | AMYRIS INC (US) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190249101-A1 | OLEFINS AND METHODS FOR MAKING THE SAME | HSD17B10, DHCR7, HSD17B12 | KMT2A 2965/4885SQLE 22/4885ALOX15 34/4885 |
| US-11193078-B2 | Olefins and methods for making the same | HSD17B10, DHCR7, HSD17B12 | KMT2A 2965/4885SQLE 22/4885ALOX15 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.